Status:
COMPLETED
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
Lead Sponsor:
Nabi Biopharmaceuticals
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.
Eligibility Criteria
Inclusion
- Subjects who are eligible for randomization or have not reached Week 12 in Nabi-4514 or Nabi-4515 studies.
- Subjects who agree to participate in health-related quality of life study.
Exclusion
- Subjects who are unable to complete a HRQoL questionnaire because of inability to understand the language or due to mental impairment.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01178346
Start Date
July 1 2010
End Date
November 1 2011
Last Update
May 9 2012
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
NicVAX Investigator
Tucson, Arizona, United States, 85724
2
NicVAX Investigator
Encino, California, United States, 91316
3
NicVAX Investigator
Los Alamitos, California, United States, 90720
4
NicVAX
Newport Beach, California, United States, 92660